Log in

Beigene Stock Forecast, Price & News

-2.27 (-0.84 %)
(As of 09/22/2020 12:00 AM ET)
Today's Range
Now: $268.80
50-Day Range
MA: $236.99
52-Week Range
Now: $268.80
Volume100,531 shs
Average Volume296,103 shs
Market Capitalization$24.30 billion
P/E RatioN/A
Dividend YieldN/A
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; and BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers. In addition, its clinical stage drugs include BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, a humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; BGB-A425, a TIM-3 inhibitor; MGCD-0516, a multi-kinase inhibitor; and CC-122, a cereblon modulator. The company has collaborations with Celgene Corporation, Merck KGaA, Mirati Therapeutics, Inc., Zymeworks, BioAtla, LLC, and Ambrx, Inc. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.
Read More
Beigene logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.15 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BGNE



Sales & Book Value

Annual Sales$428.21 million
Book Value$15.87 per share


Net Income$-948,630,000.00
Net Margins-620.47%


Market Cap$24.30 billion
Next Earnings Date11/10/2020 (Estimated)
-2.27 (-0.84 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Beigene (NASDAQ:BGNE) Frequently Asked Questions

How has Beigene's stock price been impacted by Coronavirus?

Beigene's stock was trading at $145.69 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BGNE stock has increased by 84.5% and is now trading at $268.80.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Beigene?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Beigene

When is Beigene's next earnings date?

Beigene is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Beigene

How were Beigene's earnings last quarter?

Beigene Ltd (NASDAQ:BGNE) announced its quarterly earnings results on Thursday, August, 6th. The company reported ($4.31) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($4.78) by $0.47. The business had revenue of $65.64 million for the quarter, compared to analyst estimates of $50.10 million. Beigene had a negative return on equity of 72.94% and a negative net margin of 620.47%.
View Beigene's earnings history

What price target have analysts set for BGNE?

13 Wall Street analysts have issued 1-year price targets for Beigene's stock. Their forecasts range from $165.00 to $268.00. On average, they expect Beigene's share price to reach $216.30 in the next year. This suggests that the stock has a possible downside of 19.5%.
View analysts' price targets for Beigene

Who are some of Beigene's key competitors?

What other stocks do shareholders of Beigene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beigene investors own include NVIDIA (NVDA), Alibaba Group (BABA), Crispr Therapeutics (CRSP), Square (SQ), JD.Com (JD), Intuitive Surgical (ISRG), Baidu (BIDU), Marvell Technology Group (MRVL), Editas Medicine (EDIT) and AbbVie (ABBV).

Who are Beigene's key executives?

Beigene's management team includes the following people:
  • Mr. John V. Oyler, Co-Founder, CEO & Chairman (Age 51)
  • Dr. Xiaodong Wang, Co-Founder, Chairman of the Scientific Advisory Board & Director (Age 56)
  • Dr. Heng Liang, CFO & Chief Strategy Officer (Age 56)
  • Dr. Jane E. Huang M.D., Chief Medical Officer - Hematology (Age 46)
  • Dr. Xiaobin Wu, Pres & Gen. Mang. of China

When did Beigene IPO?

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

What is Beigene's stock symbol?

Beigene trades on the NASDAQ under the ticker symbol "BGNE."

Who are Beigene's major shareholders?

Beigene's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (6.09%), Artal Group S.A. (0.95%), Matthews International Capital Management LLC (0.32%), Sumitomo Mitsui Trust Holdings Inc. (0.22%), Candriam Luxembourg S.C.A. (0.21%) and Swiss National Bank (0.17%). Company insiders that own Beigene stock include Amy C Peterson, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends for Beigene

Which major investors are selling Beigene stock?

BGNE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., Russell Investments Group Ltd., Bank of America Corp DE, Goldman Sachs Group Inc., Barclays PLC, Matthews International Capital Management LLC, and New Silk Road Investment PTE Ltd.. Company insiders that have sold Beigene company stock in the last year include Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu, and Xiaodong Wang.
View insider buying and selling activity for Beigene

Which major investors are buying Beigene stock?

BGNE stock was acquired by a variety of institutional investors in the last quarter, including Artal Group S.A., California Public Employees Retirement System, MERIAN GLOBAL INVESTORS UK Ltd, Candriam Luxembourg S.C.A., Nuveen Asset Management LLC, M&G Investment Management Ltd., Edmond DE Rothschild Holding S.A., and New York State Common Retirement Fund.
View insider buying and selling activity for Beigene

How do I buy shares of Beigene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Beigene's stock price today?

One share of BGNE stock can currently be purchased for approximately $268.80.

How big of a company is Beigene?

Beigene has a market capitalization of $24.30 billion and generates $428.21 million in revenue each year. The company earns $-948,630,000.00 in net income (profit) each year or ($15.80) on an earnings per share basis. Beigene employs 3,500 workers across the globe.

What is Beigene's official website?

The official website for Beigene is www.beigene.com.

How can I contact Beigene?

Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.